SCHEMBL17308316

SCHEMBL17308316

Cc1cc(NC2CNC2)nc(NC2COC2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ DNM2 P50570 1/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.36
▸ FLT3 P36888 2/20 0.35
▸ KCNN2 Q9H2S1 1/20 0.33
▸ KCNN3 Q9UGI6 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ KDM4E B2RXH2 3/20 0.32
▸ ATM Q13315 2/20 0.32
▸ CCNT1 O60563 1/20 0.32
▸ CDK9 P50750 1/20 0.32
▸ CAMK2D Q13557 1/20 0.32
▸ PLK4 O00444 1/20 0.32
▸ PAK4 O96013 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17303526 0.91 LMNA (0.45) LMNACYP1A2CYP2D6HTTSMN1; SMN2
SCHEMBL17306717 0.82 HRH3 (0.34) HRH3FLT3CCNT1CDK9
SCHEMBL17303994 0.80 KCNN2 (0.38) LMNACYP1A2CYP2D6HTTSMN1; SMN2
SCHEMBL17308308 0.75 MCHR1 (0.50) DNM2MEN1KMT2AKCNH2
SCHEMBL17303814 0.73 PDE4A (0.42) LMNACYP1A2CYP2D6HTTSMN1; SMN2
SCHEMBL17303756 0.72 KCNN2 (0.38) LMNACYP1A2CYP2D6HTTSMN1; SMN2
SCHEMBL17303787 0.72 KCNN2 (0.35) LMNACYP1A2CYP2D6HTTSMN1; SMN2
SCHEMBL15833940 0.72 KCNN2 (0.38) LMNACYP1A2CYP2D6HTTSMN1; SMN2
SCHEMBL15829980 0.72 KCNN2 (0.35) LMNACYP1A2CYP2D6HTTSMN1; SMN2
SCHEMBL17303780 0.72 CCNT1 (0.40) LMNACYP1A2CYP2D6HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150344434-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344434-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 LMNA 3379/4885CYP1A2 1965/4885CYP2D6 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback